RLYB116

About Rallybio

Rallybio is a publicly traded, clinical-stage biotech focused on addressing severe unmet needs in rare diseases, particularly in complement dysregulation and hematology. The company's strategy centers on leveraging its experienced leadership team's extensive network and drug development acumen to source and advance promising global candidates. Its most advanced asset, RLYB116, is in Phase 1 confirmatory studies, aiming to establish a best-in-class C5 inhibition profile. Despite a promising approach, the company faces significant financial and clinical execution risks common to early-stage biotechs.

Therapeutic Areas

Other Complement-mediated diseases Drugs